药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
Necitumumab
The risk or severity of adverse effects can be increased when Necitumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Daratumumab
The risk or severity of adverse effects can be increased when Daratumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Evolocumab
The risk or severity of adverse effects can be increased when Evolocumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Idarucizumab
The risk or severity of adverse effects can be increased when Idarucizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Dulaglutide
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Pembrolizumab
The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Nivolumab
The risk or severity of adverse effects can be increased when Nivolumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Raxibacumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Trastuzumab deruxtecan.